USX:VNRX - VolitionRX Ltd (USD 3.44) VolitionRX Ltd
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance

USD 3.44    -0.150 (-4.18%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


9 Apr 2020

Day Change: -0.150 (-4.18%)

52 Wk Range: 2.22 - 6.84

Day's Range: 3.31 - 3.68

Last Volume: 115,628

Current Yield: 0%

Projected Yield: 0%

Open: USD 3.65

9 Apr 2020

Metric VNRX S.Median
Beta 1.08 0.84
VaR 49.13 25.23
E.Shortfall 68.64 45.03
Liquidity 123.5K 95.2K


9 Apr 2020

PE: -8.398

Market Cap: 135.2M

Price Over Book: 9.522

Price Over Sales: -1,118.78

Return On Assets: -75.6%

Return On Equity: -113.4%

Price Over NAV: [Friends Only]


CEO: Cameron John Reynolds

Headquarters: SINGAPORE

Employees: 44

Sector: Health Technology

Industry: Medical Specialties

Useful Links


VolitionRx Limited, a life sciences company, focuses on developing blood-based tests to diagnose a range of cancers. The company is involved in the development of epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. It develops blood assays in the Nu.Q-X family to detect nucleosomes containing specific nucleotides; and blood assays in the Nu.Q-V family to detect nucleosomes containing specific histone variants. The company also develops blood assays in the Nu.Q-M family to detect nucleosomes containing modified histones that are proteins for packaging and ordering DNA into nucleosomes; blood assays in the Nu.Q-A family to detect nucleosome-protein adducts; and a Nu.Q-T assay to detect cancer by detecting total blood nucleosome levels. In addition, it develops HyperGenomics tissue and blood-based tests to determine disease subtype following initial diagnosis and to decide appropriate therapy; NuQ tests for non-cancer conditions; and NuQ clinical diagnostic products. VolitionRX Limited is based in Singapore.